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Antiarrhythmic and Electrophysiologic Eﬀects of Flecainide on
Acutely Induced Atrial Fibril lation in Healthy Horses
M.M. Haugaard, S. Pehrson, H. Carstensen, M. Flethøj, E.Z. Hesselkilde, K.F. Præstegaard,
J.G. Diness, M. Grunnet, T. Jespersen, and R. Buhl
Background: Only few pharmacologic compounds have been validated for treatment of atrial ﬁbrillation (AF) in
horses. Studies investigating the utility and safety of ﬂecainide to treat AF in horses have produced conﬂicting results, and
the antiarrhythmic mechanisms of ﬂecainide are not fully understood.
Objectives: To study the potential of ﬂecainide to terminate acutely induced AF of short duration (≥15 minutes), to
examine ﬂecainide-induced changes in AF duration and AF vulnerability, and to investigate the in vivo eﬀects of ﬂecainide
on right atrial eﬀective refractory period, AF cycle length, and ventricular depolarization and repolarization.
Animals: Nine Standardbred horses. Eight received ﬂecainide, 3 were used as time-matched controls, 2 of which also
received ﬂecainide.
Methods: Prospective study. The antiarrhythmic and electrophysiologic eﬀects of ﬂecainide were based on 5 parame-
ters: ability to terminate acute pacing-induced AF (≥15 minutes), and drug-induced changes in atrial eﬀective refractory
period, AF duration, AF vulnerability, and ventricular depolarization and repolarization times. Parameters were assessed
at baseline and after ﬂecainide by programmed electrical stimulation methods.
Results: Flecainide terminated all acutely induced AF episodes (n = 7); (AF duration, 21  5 minutes) and signiﬁcantly
decreased the AF duration, but neither altered atrial eﬀective refractory period nor AF vulnerability signiﬁcantly. Ventric-
ular repolarization time was prolonged between 8 and 20 minutes after initiation of ﬂecainide infusion, but no ventricular
arrhythmias were detected.
Conclusions and Clinical Importance: Flecainide had clear antiarrhythmic properties in terminating acute pacing-
induced AF, but showed no protective properties against immediate reinduction of AF. Flecainide caused temporary pro-
longation in the ventricular repolarization, which may be a proarrhythmic eﬀect.
Key words: Atrial electrophysiology; Equine; Pacing; Programmed electrical stimulation.
The utility and safety of ﬂecainide to treat atrialﬁbrillation (AF) in horses has been evaluated in a
few studies and with conﬂicting results.1–4 In acute
experimentally induced AF studies, ﬂecainide was
reported to be a safe antiarrhythmic compound with
high eﬃcacy in restoring sinus rhythm (SR) in horses
with AF of 15 minutes0 duration,1 but caused sudden
death in 1 of 2 treated horses with 7 days of AF.4 Dis-
appointing eﬃcacy and questionable safety were found
in horses with longer lasting AF, with evidence of elec-
trical and mechanical remodeling.2–4
Atrial ﬁbrillation is the most common clinically rel-
evant arrhythmia aﬀecting performance in athlete
horses.5–8 Orally administered quinidine sulfate is the pharmacologic treatment of choice for restoring SR in
horses regardless of the duration of AF,9 and has a
fairly high eﬃcacy (65–90%) in horses with no under-
lying cardiac disease.8 However, treatment frequently
is terminated because of cardiac or noncardiac adverse
eﬀects or both.9,10 Transvenous electrical cardiover-
sion (TVEC) is eﬀective in restoring SR in horses
without underlying cardiac disease with reported suc-
cess rates of approximately 90%.11,12 However, this
procedure requires specialized hospital facilities and
equipment. Hence, alternative treatment options are
desirable.
Atrial ﬁbrillation is a self-sustaining arrhythmia
characterized by rapid uncoordinated atrial activation
and irregular ventricular contractions.13 The funda-
mental mechanisms underlying AF are still debated,
but regardless of the initiating event, there is broad
consensus that AF is maintained by rapid focal activa-
tion or by re-entrant wavelets of depolarization
moving randomly across the atria.13–15 Flecainide is,
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because of its sodium channel blocking properties,
classiﬁed as a class IC antiarrhythmic drug. One of the
prominent features of ﬂecainide is slowing of the con-
duction velocity throughout the heart. However, the
exact pharmacologic mechanisms are not fully under-
stood. In vivo studies have produced conﬂicting results
with regard to ﬂecainide-induced changes in atrial
eﬀective refractory period (aERP).16–20 Flecainide may
slow the atrial activation rate and eventually terminate
AF by decreasing excitability, increasing the size and
decreasing the number of re-entrant circuits,18 primar-
ily by widening the temporal excitable gap (the diﬀer-
ence between AF cycle length [AFCL] and aERP
during AF),16,17 by changing the appearance of the
rotating wavefront or some combination of these
eﬀects.21–23 In animal tachypacing models and in
human AF patients, ﬂecainide caused increased AFCL,
decreased conduction velocity and caused a minor
tachycardia-dependent increase in aERP.17,24–29 In
horses, a marked ﬂecainide-induced increase in AFCL
has been reported,2 but the eﬀects of ﬂecainide on
aERP, AF duration, and AF vulnerability have not
yet been investigated.
The purpose of this study was to evaluate the poten-
tial of ﬂecainide to terminate acutely induced AF of
short duration and to assess the properties of ﬂecai-
nide on AF duration and AF vulnerability in healthy
horses. In addition, the acute electrophysiologic eﬀects
of ﬂecainide on aERP, AFCL, and ventricular depo-
larization and repolarization time (QRS, QTc, and
JTc) were investigated by standardized programmed
stimulation methods.30
Materials and Methods
Nine Standardbred horses were included: 3 geldings, 6 mares;
age, 7.9  3.9 years; and, body weight, 475  47 kg (Table S2 in
Data S1). Eight horses were included in a ﬂecainide group and 3
horses in a control group. Two horses participated in both
groups. The horses showed no signs of cardiovascular disease
based on history, clinical examination, thorough cardiac auscul-
tation, 24-hour ECG, and routine echocardiographic examina-
tion. The studies were approved by The Danish Animal
Experiments Inspectorate (license number 2012-15-2934-00198)
and performed in accordance with the Danish guidelines for ani-
mal experiments according to the European Commission Direc-
tive 86/609/EEC.
All experiments were performed in standing nonsedated horses
restrained in a stock. Before catheterization, injection sites were
aseptically prepared and locally anesthetizeda by using SC inﬁl-
tration. In total, 3 12-gauge IV cathetersb were placed: 2 in the
right and 1 in the left jugular vein. The left-sided catheter was
used for drug administration, blood sampling, and routine access.
The right-sided catheters were placed in the lower half of the vein
approximately 10 cm apart and replaced by introducer sheaths.c
A multipolar steerable nonﬁxative electroded was introduced
through each introducer sheath and advanced into the right
atrium: 1 for atrial pacing, and the second for recording intra-
atrial electrograms (aEGM). The electrodes were positioned in
the atrium so that deﬂections on the aEGM appeared in close
association with the beginning of the P wave on the 2 simulta-
neously recorded surface ECGs (S-ECG1 + S-ECG2), and pacing
at 60 beats per minute (bpm) resulted in consistent atrial capture.
Self-adhesive ECG electrodese were positioned as shown in Fig-
ure 1. S-ECG1 was optimized to show atrial activity (P wave
lead), whereas S-ECG2 was a modiﬁed base-apex lead focusing
on ventricular activity. In S-ECG1, the positive electrode was
adjusted dorso-ventrally until the recorded P wave had the high-
est amplitude possible. Both intra-atrial and surface ECGs were
Fig 1. ECG leads. S-ECG1 and S-ECG2: surface ECGs recorded simultaneously during the experiments. S-ECG3: modiﬁed base-apex
surface ECG recorded during and 12–24 hours after the experiment. +//ref indicate positive, negative, and reference electrodes, respec-
tively. Arrows at S-ECG1+ indicate that this electrode was adjusted dorso-ventrally until the recorded P wave had the highest amplitude
possible.
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monitored during the experiments and storedf for later analysis.
Furthermore, an additional surface ECG (S-ECG3) identical to
S-ECG2 was recorded with the Televet systeme and continued for
12–24 hours after the experiment. The experimental protocol of
the study is demonstrated in Figure 2.
Atrial Eﬀective Refractory Period
A constant pulse width of 2 milliseconds was used throughout
the experiment. Measurements of aERP were conducted using
twice baseline atrial pacing threshold. The aERP was determined
once before and once after ﬂecainide treatment at atrial pacing
rates of 60, 75, 120, and 182 bpm, respectively. aERP was mea-
sured with 10 basic stimuli (S1) followed by an extra stimulus
(S2) applied with 10 milliseconds increments, and was deﬁned as
the longest S1–S2 failing to elicit a new action potential. Every
S1–S2 interval was applied multiple times (5–10 repetitions) at
each pacing rate, and if intermittent atrial capture occurred, the
S2 value below the one with ≥50% captures was deﬁned as the
aERP.
Atrial Fibrillation Cycle Length
Atrial ﬁbrillation cycle length was measured as a surrogate for
tissue refractoriness, and represents the time interval between
consecutive atrial depolarizations. In the present study, AFCL
was determined by manually analyzing 15-second sequences on
the aEGM the last 15 seconds before the initiation of ﬂecainide
treatment and repeated in the last 15 seconds before AF
termination.
Induction of AF and Flecainide Treatment
Atrial ﬁbrillation was repeatedly induced using programmed
electrical stimulation. A comprehensive induction protocol was
used because the sensitivity of horses to induced AF has not been
described previously, and because detailed information was
needed to evaluate possible ﬂecainide-induced changes in AF
duration and AF vulnerability. A schematic outline of the induc-
tion protocol is illustrated in Figure 3. The duration of each tac-
hypacing period was 2–6 seconds (Table S3 in Data S1). If the
duration of an induced AF episode exceeded 5 minutes at any
given induction setting, tachypacing was repeated 5 times. If epi-
sodes were shorter than 5 minutes, 10–15 inductions were made
and mean AF duration was calculated. Comparisons (baseline
versus post-ﬂecainide) were based on results obtained at the base-
line induction setting capable of inducing a mean AF duration
>1 minute. In addition, the ﬁrst single AF episode >1 minute in
duration deﬁned AF vulnerability (for vulnerability scoring, see
Table S1 in Data S1). If only a few or short-lasting AF episodes
A B C
D E F
Fig 2. The experimental protocol of the study based on ECG recordings. To emphasize that the same protocol was used before and
after ﬂecainide, identical ECG sequences are presented in B and E and in C and F. (A) Positioning of electrodes and atrial pacing
threshold determination. (B) atrial eﬀective refractory period (aERP) measurements at multiple atrial pacing rates (60, 75, 120, and
182 bpm). (C) Atrial ﬁbrillation (AF) duration and AF vulnerability measurements. AF was induced and the time to cardioversion at
diﬀerent induction settings (see Fig 3) was recorded. (D) If AF ≥ 15 minutes occurred horses were treated with ﬂecainide (2 mg/kg IV)
and cardioversion times recorded. (E) Repeated threshold determination and measurements of aERP at identical atrial pacing rates as
before ﬂecainide treatment. (F) Remeasuring of AF duration and AF vulnerability as described under (C). : A black mark under a P
wave indicates a second degree AV block. Arrow in (B) and (E): S2 stimuli associated with atrial capture. Arrow in (C) and (F): Tac-
hypacing period leading to AF and subsequent spontaneous cardioversion.
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were induced, the stimulation frequency was stepwise increased
and at the ﬁnal step (burst pacing at 3,000 bpm; ie, 50 Hz), the
current was subsequently increased (Fig 3). Whenever an AF epi-
sode exceeded 15 minutes in duration, AF termination was
attempted by IV infusion of ﬂecainideg (2 mg/kg) over 10 minutes
according to previous recommendations.1 If no AF episodes
≥15 minutes occurred and spontaneous termination occurred
repeatedly, horses were treated with ﬂecainide while in SR. Seven
horses were treated while in AF; 1 while in SR. After ﬂecainide
infusion, aERP measurements and AF induction protocols were
repeated. Subsequently, the eﬀects of ﬂecainide on AF duration
and AF vulnerability were assessed. Blood pressureh (noninvasive)
and blood samplesi were collected at baseline and at speciﬁc time
points after ﬂecainide treatment to evaluate ﬂecainide-induced
changes (for details see Data S1).
Time-Matched Control Studies
Three horses were assigned to participate in time-matched con-
trol studies. Two horses completed the control study after a ﬂe-
cainide wash-out period, whereas the last horse was included
only in the control group. The control studies followed a proto-
col as described for the ﬂecainide studies except that only iso-
tonic saline was infused instead of ﬂecainide. After infusion, the
horses were monitored for spontaneous cardioversion for 30 min-
utes. If a horse was still in AF after 30 minutes, the experiment
was ended and the horse was released from all equipment includ-
ing intracardiac electrodes. However, S-ECG3 was left in position
to capture the exact cardioversion time.
Analysis of ECG Intervals
QT intervals and QRS durations were manually analyzed on
S-ECG2; JTc intervals were calculated as (QTc minus QRS).
Representative ECG tracings illustrating QT and QRS measure-
ments in SR and AF, as well as information regarding QRS/
QTc-methods are provided in Data S1. Heart rate was calculated
in the same sections as QRS and QT were measured.
Data Analysis
Results are presented as mean  SD. Statistical analyses were
performed by specialized software.j All datasets were normally
distributed allowing the use of parametric tests. However, loga-
rithmic transformation of AF duration data was necessary to
accomplish normal distribution. The combined eﬀects of ﬂecai-
nide and atrial stimulation rates on aERP were examined by
2-way repeated-measures ANOVA followed by Bonferroni0s
posthoc test. A paired t-test was used to analyze ﬂecainide-
induced changes in AF duration, whereas a Wilcoxon matched
pairs t-test was used to compare changes in AF vulnerability.
Flecainide-induced changes in blood pressure (MAP), heart rate,
Fig 3. Flow diagram illustrating the atrial ﬁbrillation (AF) induction protocol. For each horse, AF duration and AF vulnerability were
measured at the induction setting capable of inducing AF episodes exceeding 1 minute in duration (see text). npre and npost represent the
number of horses entering AF ≥ 15 minutes at that particular induction setting before and after ﬂecainide treatment, respectively.
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QRS, QTc, and JTc interval were analyzed by 1-way repeated
ANOVA followed by Dunnett0s posthoc test using the time point
just before initiated infusion of ﬂecainide as reference
(Time  1). P<.05 was considered statistically signiﬁcant.
Results
To investigate the electrophysiologic eﬀects of ﬂecai-
nide, we examined the atrial pacing threshold, AFCL,
and aERP before and after infusion of ﬂecainide. Fle-
cainide did not alter the atrial pacing threshold com-
pared to baseline (1.0  0.9 versus 0.8  0.5; Table S2
in Data S1). AFCL increased signiﬁcantly before ﬂe-
cainide-induced AF termination compared to baseline
with a mean increase of 35  19% (P < .001; Table S2
in Data S1). However, treatment with ﬂecainide did
not result in statistically signiﬁcant changes in aERP
at any stimulation rate (Fig 4). Faster atrial pacing
rate resulted in a decrease in aERP (P = .014;
Table S3 in Data S1).
The antiarrhythmic potential of ﬂecainide was stud-
ied by evaluating drug-induced termination time,
changes in AF duration and AF vulnerability. The
outcome of the induction protocol varied markedly
among horses. However, AF episodes of variable dura-
tion were induced in all horses. Three of 8 horses were
highly sensitive and developed AF episodes ≥15 min-
utes during baseline aERP measurements at an atrial
pacing rate of 182 bpm (Table S3 in Data S1). In
total, 7 of 8 horses developed AF ≥ 15 minutes during
the baseline protocol and were treated with ﬂecainide
while in AF. Duration of the last AF episode before
initiation of treatment was 21  5 minutes (Table S3
in Data S1). In 1 horse, spontaneous AF termination
occurred repeatedly, and only several short episodes of
AF could be induced, and thus, this horse received ﬂe-
cainide while in SR. The 7 horses treated with ﬂecai-
nide while in AF, all cardioverted to SR during
ﬂecainide infusion with a termination time of
4.6  2.5 minutes (Table S3 in Data S1).
Post-ﬂecainide AF inductions were initiated
42  13 minutes and ended 72  24 minutes after
completed infusion. Plasma concentrations of ﬂecai-
nide (ng/mL) 1 minute to 24 hours after completed
infusion are illustrated in Figure 5 and plasma half-life
(T½) values are presented in Table S4 in Data S1. The
ﬂecainide-induced changes in AF duration and AF
vulnerability are shown in Figure 6A,B. All horses
completed the post-treatment aERP protocol without
developing any AF episodes ≥15 minutes. Flecainide
signiﬁcantly shortened AF duration (P = .003; Fig 6A,
Table S3 in Data S1), but had no statistically signiﬁ-
cant eﬀect on AF vulnerability (P = .136; Fig 6B,
Table S3 in Data S1).
Baseline MAP was 78  12 mmHg. Flecainide did
not signiﬁcantly change MAP during a 60-minute per-
iod after completion of infusion compared to baseline
(Fig 7).
To evaluate ﬂecainide-induced changes in the ven-
tricular conduction pattern, we examined changes in
HR, and QRS, QTc, and JTc intervals. QRS, QTc,
and JTc were prolonged between 8 and 30 minutes, 6
and 25 minutes, and 8 and 20 minutes after initiation
of ﬂecainide infusion, respectively (Fig 8A,C,D). HR
was calculated over 20  1.8 beats and was stable
throughout the experiments (Fig 8B). No ventricular
arrhythmias were detected during infusion and in a 90-
minute period after ﬂecainide treatment.
Control Studies
To measure AFCL at comparable time points in the
ﬂecainide and in control groups, AFCL after saline
infusion was measured at the previously recorded time
of cardioversion from AF to SR after ﬂecainide infu-
sion (4.6 minute after starting infusion = during infu-
Fig 4. Baseline and ﬂecainide-induced changes in right atrial
eﬀective refractory period (aERP) at 60, 75, 120, and 182 bpm,
respectively, in healthy Standardbred horses (n = 8).
Fig 5. Flecainide plasma concentrations 1 minute to 24 hours
after completed infusion of ﬂecainide (2 mg/kg IV over 10 min-
utes) in healthy Standardbred horses (n = 7). Note that the Y-
axis is log-transformed. For details, please see Table S3 in
Data S1.
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sion). Baseline atrial pacing threshold, pre-saline AF
duration, pre-saline AFCL, AFCL at 4.6 minutes after
saline infusion was started, and baseline aERP at 60
and 182 bpm in the control experiments are presented
in Table S5 in Data S1. All 3 horses developed AF
episodes ≥15 minute during the baseline protocol with
a mean AF duration of 22  5 minutes before saline
infusion was started. AF was not terminated by saline
infusion, and spontaneous termination time was
5.8  3.2 hours (Table S5 in Data S1).
Discussion
This study was designed to investigate ﬂecainide-
induced eﬀects on atrial electrophysiology in horses
with acutely induced AF of short duration. We
assessed the antiarrhythmic potential of ﬂecainide by
its cardioversion potential and eﬀects on AF duration
and AF vulnerability. The in vivo electrophysiologic
proﬁle of ﬂecainide was evaluated by changes in
aERP, AFCL, QRS, QTc, and JTc.
Flecainide is a clinically important compound in
human patients with paroxysmal AF, but for safety
reasons, candidates for treatment are carefully selected
and the use of ﬂecainide is restricted to patients with-
out structural heart disease and with preserved left
ventricular function.31,32 When these criteria are ful-
ﬁlled, treatment with ﬂecainide demonstrates cardio-
version rates of 57–92% in human patients with AF of
short duration.32 Flecainide terminated all AF episodes
in the present study with a termination time compara-
ble to that observed in previous studies,1,27 and at the
evaluated stimulation rates, the presented baseline val-
ues of aERP in horses were consistent with those
reported by others.4,33 Our study identiﬁed no ﬂecai-
nide-induced changes in aERP, indicating that ﬂecai-
nide did not have an inﬂuence on atrial repolarization
at the chosen stimulation rates. Depending on the
model, ﬂecainide has been reported to have variable
eﬀects on aERP in vivo.16–20 In humans, some
reported a slight but not signiﬁcant ﬂecainide-induced
increase in aERP, whereas others reported signiﬁcant
and use-dependent increases.20,34 A ﬂecainide-induced
reduction in aERP accommodation to atrial activation
rates, which may be important in suppressing AF, has
been demonstrated by others.18,34–36 However, this
mechanism of rate-dependency and increased drug
action at rapid atrial activation rates could not be pro-
ven by the present study. Still, despite the lack of
aERP prolongation at the atrial rates measured in the
present study, we cannot rule out possible increases in
A B
Fig 6. Antiarrhythmic and potential protective eﬀects of ﬂecainide. Results presented as box plot, whiskers represent minimum to maxi-
mum values. (A) Atrial ﬁbrillation (AF) duration at baseline and after ﬂecainide treatment, **P = .003. Note that the Y-axis is log-trans-
formed. (B) AF vulnerability at baseline and after ﬂecainide treatment, ns: nonsigniﬁcant, P = .136. For each horse, AF duration was
measured and compared using the AF induction setting shown at baseline to be eﬀective at inducing AF episodes with a mean duration
>1 minute (see text). For each horse, AF vulnerability was measured and compared using the AF induction setting shown to be eﬀective
at inducing a single AF episode >1 minute in duration before and after ﬂecainide, respectively.
Fig 7. Flecainide-induced (2 mg/kg IV) changes in blood pres-
sure in healthy Standardbred horses (n = 8).
344 Haugaard et al
aERP during the rapid rates typical of AF. Our obser-
vations are in agreement with results from studies con-
ducted in goats where aERP was unaﬀected, AFCL
increased, and AF vulnerability unchanged by ﬂecai-
nide.17,24 The variable ﬂecainide-induced changes in
aERP may be related to species diﬀerences and spe-
cies-speciﬁc atrial ion channel composition.
Atrial ﬁbrillation cycle length shortens when AF is
maintained,4,27,37,38 prolongs immediately before spon-
taneous or drug-induced termination18 and might pro-
vide a risk assessment for AF recurrence.38 The
observed ﬂecainide-induced increase in AFCL in the
present study correlated well with the individual termi-
nation time (Tables S2, S3 in Data S1). However, in 2
horses the termination times were strikingly short and
correlated with very limited increases in AFCL, indi-
cating a questionable drug-related termination of AF.
However, in the majority of horses, the ﬂecainide-
induced increase in AFCL corresponded well with
results reported by others.2,17,24,27 A single study inves-
tigating ﬂecainide-induced changes in AFCL in horses
with spontaneous AF reported comparable increases,
nevertheless none of the treated horses cardioverted in
response to treatment.2 These conﬂicting results can
most likely be explained by the diﬀerence in AF dura-
tion and hence diﬀerences in the degree of electrical
remodeling. Van Loon et al. reported baseline AFCL
values approximately 30 milliseconds shorter than
ours, which supports the assumption of extensive elec-
trical remodeling in the previous study.2 These ﬁndings
emphasize the notion that AF should be terminated as
quickly as possible to prevent electrophysiologic
remodeling which will potentially drive the tissue into
the cycle of “AF begets AF.”
In the present study, we found a ﬂecainide-induced
decrease in induced AF duration, but no signiﬁcant
inﬂuence on AF vulnerability. No previous studies that
were methodically comparable with regard to ﬂecai-
nide-induced changes in AF duration and AF vulnera-
bility were found in the literature. However, a study in
dogs, investigating ﬂecainide0s properties against AF-
promoted electrical remodeling identiﬁed no beneﬁt of
ﬂecainide on either of the 2 parameters, and a goat
model showed 100% reinducibility of AF after cardio-
version with ﬂecainide.24,39 The results from the pres-
ent study suggest that ﬂecainide is eﬀective in
terminating acutely induced AF of short duration, has
a positive diminishing eﬀect on AF duration but does
not protect against immediate reinduction of induced
AF in healthy horses.
The safety proﬁle of ﬂecainide was evaluated by ﬂe-
cainide-induced changes in QRS and QTc. QRS
A B
C D
Fig 8. Flecainide-induced (2 mg/kg IV) changes in QRS (A), heart rate (B), QTc (C), and JTc (D) in healthy Standardbred horses
(n = 8). Time (minute): T0 and T10 represent the beginning and end of ﬂecainide infusion, respectively. Asterisks indicate the signiﬁ-
cance level compared to baseline (T-1); *P < .05, **P < .01, ***P < .001.
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durations were measured as a surrogate for the eﬀect of
ﬂecainide on ventricular conduction velocity, and our
results were in agreement with results reported by oth-
ers.1,2 Because of sodium channel blockade, and hence
depressant eﬀects on cardiac conduction, a ﬂecainide-
induced widening of QRS was expected.20,40 In humans,
recommendations are that ﬂecainide treatment should
be discontinued if QRS prolongation exceeds 25% of
baseline.36,41 The same limit of 25% is used in equine
medicine to suggest quinidine toxicity,42 but such rec-
ommendations are not available for ﬂecainide. How-
ever, because both quinidine and ﬂecainide are sodium
channel blockers, it might be reasonable to expect a sim-
ilar limit to indicate ﬂecainide toxicity. Toxicity was not
indicated in any of the horses included in the present
study because the maximum widening of QRS did not
exceed 25% at any time during the experiments. How-
ever, the eﬀect of ﬂecainide is use-dependent, and there-
fore ﬂecainide-induced changes in QRS may be
increased at higher heart rates than reported in the pres-
ent study. To investigate whether ﬂecainide aﬀected ven-
tricular repolarization, we evaluated changes in QTc
and JTc intervals. In a previous study of horses, no ﬂe-
cainide-induced changes in QT intervals were reported.1
In our study, QTc was signiﬁcantly prolonged between 6
and 25 minutes after ﬂecainide infusion was started. To
obtain a more speciﬁc ventricular repolarization time,
JTc intervals were calculated, and in contrast to what
has been documented in humans,20 ﬂecainide temporar-
ily prolonged JTc in horses. The present study however
did not identify any potentially dangerous ventricular
arrhythmias, which is in agreement with other studies.1,3
However, 3 cases of ﬂecainide-induced wide QRS-tachy-
cardia have been reported in horses2,4 of which 1 epi-
sode led to ventricular ﬁbrillation and sudden cardiac
death. Combined with the altered ventricular repolariza-
tion observed in the present study, it is important to rec-
ognize the potential proarrhythmic properties of
ﬂecainide.
Acutely induced AF in horses is a unique technique
to mimic AF. The present study reports results on pac-
ing-induced short episodes of AF in healthy horses
and the applicability to longer lasting spontaneous AF
is therefore uncertain. Two studies investigated the
antiarrhythmic potential and safety of ﬂecainide on
longer lasting naturally occuring AF in horses and
reported disappointing results.2,3 Only 1 of 14 attempts
to terminate naturally occuring AF restored SR. In
addition, the horse that responded positively to treat-
ment had recent-onset AF of only 12 days0 duration.
Another study used ﬂecainide to cardiovert persistent
burst pacing-induced AF of 7 days0 duration. Only 1
of 2 horses regained SR.4 Such observations support
the theory of AF duration being an extremely impor-
tant parameter when estimating the potential eﬃcacy
of ﬂecainide, and that treatment with antiarrhythmic
drugs always carries a risk of inducing devastating
ventricular arrhythmias.
In conclusion, ﬂecainide had clear antiarrhythmic
eﬀects terminating acute pacing-induced AF of short
duration (21 minutes) and resulted in decreased AF
duration in healthy horses, but ﬂecainide had no pro-
tective properties against immediate reinduction of AF
and caused temporary prolongation in ventricular
repolarization, which may be a potentially dangerous
proarrhythmic eﬀect.
Footnotes
a Carbocain 20 mg/kg, AstraZeneca, Copenhagen, DK
b Intraﬂon 2 (PTFE), 12G, Vycon, Wiltshire, UK
c One Piece/Tuohy-Borst Catheter Introducer with Integral
Hemostasis Valve, 8F, Argon Medical Devices, Holte, DK
d Inquiry Steerable Diagnostic Catheter, 6F/110 cm, St. Jude
Medical, Inc, Glostrup, DK
e Kruuse, Langeskov, DK
f LabChart 7 Pro, ADInstruments, Oxford, UK
g Tambocor, 10 mg/mL, Meda AS, Allerød, DK
h PM-9000Vet, Portable Veterinary Monitor, Mindray, tail-cuﬀ
system
i Venosafe Lithium Heparin tubes, 9 mL, Terumo, SE
j GraphPad Prism 5 Software, San Diego, CA
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